Similar articles

• [Drug therapy of intractable Mycobacterium infections].

  Kuze F. Kuze F. Nihon Naika Gakkai Zasshi. 1990 Dec 10;79(12):1674-9. Nihon Naika Gakkai Zasshi. 1990. PMID: 2079590 Japanese. No abstract available.
• The impact of MDT implementation in the Tanzania National TB-Leprosy Programme.

  Chum HJ. Chum HJ. Lepr Rev. 1986;57 Suppl 3:63-6. doi: 10.5935/0305-7518.19860096. Lepr Rev. 1986. PMID: 3573963 No abstract available.
• The Malta experience. Isoprodian-rifampicin combination treatment for leprosy.

  Depasquale G. Depasquale G. Lepr Rev. 1986;57 Suppl 3:29-37. doi: 10.5935/0305-7518.19860090. Lepr Rev. 1986. PMID: 3573957 No abstract available.
• Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.

  Bucaretchi F, Vicente DC, Pereira RM, Tresoldi AT. Bucaretchi F, et al. Rev Inst Med Trop Sao Paulo. 2004 Nov-Dec;46(6):331-4. doi: 10.1590/s0036-46652004000600006. Epub 2005 Jan 10. Rev Inst Med Trop Sao Paulo. 2004. PMID: 15654479 Review.
• [Immuno-allergic accidents with rifamipcin].

  Flageul B, Wagner L, Cottenot F. Flageul B, et al. Acta Leprol. 2001-2002;12(2):71-8. Acta Leprol. 2001. PMID: 12136739 Review. French.